Objective: To evaluate the utility of Sudoscan as possible marker of disease progression and disease onset in a cohort of hereditary ATTR amyloidosis (hATTR amyloidosis) polyneuropathy patients and carriers. Patients and methods: We regularly performed different clinical scales, nerve conductions studies (NCS), and Sudoscan on a cohort of hATTR amyloidosis patients and carriers from a single centre of central Italy, a non-endemic area, in the last 2 years. Results: About 18 hATTR amyloidosis patients and 8 asymptomatic carriers were enrolled. All patients had a neuropathy affecting large fibres, small fibres or both. Two subjects developed symptoms and neurophysiological alterations during follow-up. Sudoscan data from hand and feet inversely correlated with neuropathy severity and with disease duration. Moreover, global disease status, expressed by Kumamoto scale also inversely correlated with Sudoscan values. Conclusions: We confirmed that Sudoscan is a reliable marker of disease progression in late-onset hATTR amyloidosis patients and we suggest its possible utility in early detection of disease in this population.

Luigetti, M., Bisogni, G., Romano, A., Di Paolantonio, A., Barbato, F., Primicerio, G., Rossini, P. M., Servidei, S., Sabatelli, M., Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian Centre, <<AMYLOID>>, 2018; 25 (4): 242-246. [doi:10.1080/13506129.2018.1545640] [http://hdl.handle.net/10807/130693]

Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian Centre

Luigetti, Marco
;
Romano, Angela;Di Paolantonio, Andrea;Barbato, Francesco;Rossini, Paolo Maria;Servidei, Serenella;Sabatelli, Mario
2018

Abstract

Objective: To evaluate the utility of Sudoscan as possible marker of disease progression and disease onset in a cohort of hereditary ATTR amyloidosis (hATTR amyloidosis) polyneuropathy patients and carriers. Patients and methods: We regularly performed different clinical scales, nerve conductions studies (NCS), and Sudoscan on a cohort of hATTR amyloidosis patients and carriers from a single centre of central Italy, a non-endemic area, in the last 2 years. Results: About 18 hATTR amyloidosis patients and 8 asymptomatic carriers were enrolled. All patients had a neuropathy affecting large fibres, small fibres or both. Two subjects developed symptoms and neurophysiological alterations during follow-up. Sudoscan data from hand and feet inversely correlated with neuropathy severity and with disease duration. Moreover, global disease status, expressed by Kumamoto scale also inversely correlated with Sudoscan values. Conclusions: We confirmed that Sudoscan is a reliable marker of disease progression in late-onset hATTR amyloidosis patients and we suggest its possible utility in early detection of disease in this population.
Inglese
http://www.tandfonline.com/loi/iamy20
Luigetti, M., Bisogni, G., Romano, A., Di Paolantonio, A., Barbato, F., Primicerio, G., Rossini, P. M., Servidei, S., Sabatelli, M., Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: experience from an Italian Centre, <>, 2018; 25 (4): 242-246. [doi:10.1080/13506129.2018.1545640] [http://hdl.handle.net/10807/130693]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/130693
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
social impact